Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis

OBJECTIVES: To determine the safety, pharmacokinetics (PK), and immunogenicity of the recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with multiple sclerosis (MS) with clinical or MRI activity. METHODS: In this 20-week, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Constantinescu, Cris S., Asher, Aliya, Fryze, Waldemar, Kozubski, Wojciech, Wagner, Frank, Aram, Jehan, Tanasescu, Radu, Korolkiewicz, Roman P., Dirnberger-Hertweck, Maren, Steidl, Stefan, Libretto, Susan E., Sprenger, Till, Radue, Ernst W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442097/
https://www.ncbi.nlm.nih.gov/pubmed/26185773
http://dx.doi.org/10.1212/NXI.0000000000000117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442097/
https://www.ncbi.nlm.nih.gov/pubmed/26185773
http://dx.doi.org/10.1212/NXI.0000000000000117

Ejemplares similares